Name: BioNexus Gene Lab Corp. (BGLC) Cash Flow Statement
Creator: FinSpry

BioNexus Gene Lab Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for BioNexus Gene Lab Corp. (BGLC) - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Operating Activities
Net Income	-1.60	-2.63	-0.36	0.75	1.09
Depreciation & Amortization	0.15	0.11	0.11	0.11	0.10
Stock Based Compensation	0.00	0.51	0.00	0.00	0.00
Change in Working Capital	0.12	0.12	0.83	-0.86	0.10
Change in Accounts Receivable	0.15	0.65	0.54	0.58	0.41
Change in Inventory	-0.25	-0.16	0.54	-0.35	0.15
Change in Accounts Payable	0.20	-0.38	-0.12	-1.18	-0.52
Change in Other Working Capital	0.03	0.01	0.01	-0.06	0.04
Other Operating Activities	0.03	0.01	0.01	-0.02	-0.01
Net Cash from Operating Activities	-2.23	-1.82	0.55	0.01	0.55
Investing Activities
Capital Expenditures	-0.23	-0.15	-0.05	0.00	-0.42
Acquisitions	0.00	0.00	0.00	0.00	0.35
Purchases of Investments	-0.57	-1.73	-0.51	-0.51	-0.08
Sales/Maturities of Investments	1.07	0.03	0.00	0.01	0.00
Other Investing Activities	0.07	-1.35	0.12	0.02	0.01
Net Cash from Investing Activities	0.42	-1.79	-0.45	-0.49	1.32
Financing Activities
Debt Repayment	0.00	0.00	-0.03	-0.03	0.00
Common Stock Issued	0.14	6.26	0.15	0.00	0.00
Other Financing Activities	0.14	6.27	0.15	0.00	0.00
Net Cash from Financing Activities	0.14	6.27	0.11	-0.03	0.00
Summary
Effect of Forex Changes on Cash	0.04	-0.26	-0.21	-0.15	0.00
Net Change in Cash	-1.67	2.66	0.21	-0.66	1.93
Cash at Beginning of Period	4.52	2.12	2.12	2.79	0.00
Cash at End of Period	2.89	4.52	2.12	2.12	0.00
Free Cash Flow	-2.46	-1.97	0.50	0.01	0.13
Supplemental Disclosures
Interest Paid	0.01	0.01	0.01	0.01	0.01
Income Taxes Paid	0.04	0.07	0.17	0.23	0.13